Skip to main content
. 2024 Jul 26;13(7):3783–3797. doi: 10.21037/tcr-24-747

Table 1. Characteristics of the included studies.

Author, year Country Intervention Sample size Gender (male/female) Age (years) Outcomes
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
Han, 2022 (15) China NIL 300 mg BID IM 400 mg QD 34 34 20/14 19/15 20–55a 18–66a ① ② ③ ④ ⑤
Brümmendorf, 2022 (16); Cortes, 2018 (17) Global, multicenter BOS 400 mg QD IM 400 mg QD 268 268 156/112 155/113 52 [18–84]b 53 [19–84]b ① ② ③ ⑤ ⑦ (5 years) ⑧ ⑨ ⑩ ⑪ ⑫ ⑬
NCT00481247 (18); Jabbour, 2014 (19); Kantarjian, 2012 (20); Kantarjian, 2010 (21) Global, multicenter DAS 100 mg QD IM 400 mg QD 259 260 141/115 163/97 46 [18–84]b 49 [18–78]b ③ ⑤ ⑥ (2, 3, 5 years) ⑦ (2, 3, 5 years) ⑨ ⑩ ⑪
Li, 2021 (22) China NIL 300–400 mg BID IM 400 mg QD 39 39 22/17 23/16 48.25±6.71c 47.03±6.42c ⑤ ⑥ (3 years) ⑦ (3 years)
Yu, 2021 (23) China DAS 70 mg QD DAS 100 mg QD 29 22 13/16 15/7 47.13±15.15c 43.59±14.36c ② ③ ④ ⑤ ⑫
Wang, 2020 (24) China NIL 400 mg BID DAS 100 mg QD 12 13 7/5 7/6 35–65a 35–65a ③ ⑤ ⑧
Cortes, 2020 (25) Global, multicenter IM ≥400 mg OD or BID DAS 100mg QD 86 174 70/16 133/41 40 [18–73]b 35 [18–82]b ③ ⑥ (2 years) ⑦ (2 years) ⑧ ⑨ ⑩ ⑪
Zhang, 2021 (11) China FLU 600 mg QD IM 400 mg QD 196 197 126/70 119/78 45 [20–70]b 45 [18–73]b ② ③ ④ ⑤ ⑨ ⑩ ⑪ ⑫ ⑬
Geng, 2018 (26) China DAS 100 mg QD IM 400 mg QD 44 43 28/16 26/17 42.8±6.5c 43.1±6.8c ⑤ ⑧ ⑫
Wang, 2017 (27) China DAS 100 mg QD IM 400 mg QD 10 10 7/3 6/4 40.25±10.13c 41.15±10.21c ⑤ ⑧ ⑫
Kwak, 2017 (28) Global, multicenter IM 400 mg QD; RAD 400 mg BID RAD 300 mg BID 81; 81 79 50/31; 47/34 52/27 45 [18–83]b; 43 [18–84]b 45 [20–75]b ① ② ③ ④ ⑤ ⑨ ⑩ ⑪ ⑫ ⑬
Hehlmann, 2017 (29) Germany, Switzerland IM 800 mg QD IM 400 mg QD 420 400 248/172 244/156 51 [18–85]b 53 [16–88]b ③
Lu, 2016 (30) China DAS 100 mg QD IM 400 mg QD 20 20 11/9 10/10 20–61a 20–60a ⑤ ⑧ ⑫
Liu, 2016 (31) China FLU 400 mg QD; FLU 600 mg QD IM 400 mg QD 8; 9 7 15/9 38d ③
Wang, 2016 (32) China NIL 300 mg BID; DAS 100 mg QD IM 400 mg QD 32; 32 32 17/15; 18/14 16/16 41.53±3.81c; 40.14±4.23c 39.81±3.25c ① ② ③ ④ ⑤ ⑧
Hjorth-Hansen, 2015 (33) Finland, Norway, Sweden DAS 100 mg QD IM 400 mg QD 22 24 7/15 15/9 53 [29–71]b 58 [38–78]b ④ ⑤ ⑨ ⑩ ⑪
Zheng, 2013 (34) China DAS 100mg QD IM 400 mg QD 13 12 NR NR NR NR ⑤
Radich, 2012 (35) United States, Canada IM 400 mg QD DAS 100 mg QD 123 123 72/51 74/49 50 [19–89]b 47 [18–90]b ⑤ ⑪
Cortes, 2012 (36) Global, multicenter BOS 500 mg QD IM 400 mg QD 250 252 149/101 135/117 48 [19–91]b 47 [18–89]b ⑨ ⑩ ⑪ ⑫ ⑬
Hehlmann, 2011 (37) Global, multicenter IM 800 mg QD IM 400 mg QD 338 325 199/139 195/130 52 [18–86]b 54 [16–88]b ② ③ ④ ⑤ ⑨ ⑩ ⑪
Saglio, 2010 (38) Global, multicenter IM 400 mg QD; NIL 400 mg BID NIL 300 mg BID 283; 281 282 158/125; 175/106 158/124 46 [18–80]b; 47 [18–81]b 47 [18–85]b ① ② ③ ④ ⑤ ⑧ ⑫ ⑬
Preudhomme, 2010 (39) France IM 400 mg QD IM 600 mg QD 159 160 109/50 89/71 50d 51d ③ ④ ⑤
Petzer, 2010 (40) Austria IM 800 mg QD IM 400 mg QD 113 113 53/58 48/63 46.5±12.3c 45.5±13.4c ④
Cortes, 2010 (41) Global, multicenter IM 800 mg QD IM 400 mg QD 319 157 183/136 84/73 48 [18–75]b 45 [18–75]b ① ② ③ ④ ⑤
Baccarani, 2009 (42) Italy IM 800 mg QD IM 400 mg QD 108 108 60/48 62/46 51 [18–84]b 56 [18–81]b ① ② ③ ④ ⑤

a, minimum-maximum; b, median [Q1–Q3]; c, mean ± SD; d, mean. ① MMR rate at 3 months; ② MMR rate at 6 months; ③ MMR rate at 12 months; ④ CCyR rate at 6 months; ⑤ CCyR rate at 12 months; ⑥ PFS rate; ⑦ OS rate; ⑧ overall incidence of adverse events; ⑨ incidence of grade 3 or above anemia; ⑩ incidence of grade 3 or above thrombocytopenia; ⑪ incidence of grade 3 or above neutropenia; ⑫ incidence of ALT elevation of all grade; ⑬ incidence of AST elevation of all grade. IM, imatinib; QD, quaque die; BID, bid twice a day; DAS, dasatinib; NIL, nilotinib; BOS, bosutinib; FLU, flumatinib; RAD, radotinib; MMR, major molecular response; CCyR, complete cytogenic response; PFS, progression-free survival; OS, overall survival; ALT, alanine aminotransferase; AST, aspartate aminotransferase.